BI-1347

BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM) . BI-1347 shows anti-tumoral activity[1][2].

Product Specifications

CAS Number

[2163056-91-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bi-1347.html

Purity

99.84

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(N(C)C)CN1N=CC(C2=CC=C(C3=CN=CC4=C3C=CC=C4)C=C2)=C1

Molecular Formula

C22H20N4O

Molecular Weight

356.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Harald Engelhardt, et al. New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors.|[2]Hofmann MH, et al. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance. Mol Cancer Ther. 2020 Apr;19 (4) :1018-1030.